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Purpose: To use localized correlated spectroscopy (COSY) to assess 
for an altered biochemical state or states in breast tissue 
of women with BRCA gene mutations that potentially con-
stitute preinvasive conditions.
Materials and 
Methods:
Institutional review board approval was obtained. Partici-
pants provided written informed consent. In vivo localized 
COSY images were recorded at 3 T in the breast tissue of 
women carrying BRCA1 (n = 9) or BRCA2 (n = 14) gene 
mutations and were compared with images in healthy 
control subjects with no family history of breast cancer 
(n = 10). All participants underwent contrast material–
enhanced MR imaging and ultrasonography (US). Statis-
tical significance was calculated with the Mann-Whitney 
two-sided nonparametric test.
Results: No abnormality was recorded with MR imaging or US. 
Metabolite levels in the BRCA1 cohort were reduced by 
79% (P = .014) when compared with triglycerides level, 
and there was a 19% increase in lipid unsaturation and 
triglyceride levels (P = .027 and P = .086, respectively) 
when compared with cellular cholesterol level. Choles-
terol level was reduced by 47% (P = .027) when compared 
with diallylic lipid level. Metabolite levels in the BRCA2 
cohort showed increased unsaturation of 21% (P = .030) 
relative to triglycerides level. Comparison of the BRCA1 
and BRCA2 cohorts showed a 47% (P = .002) increase 
in cholesterol level in the BRCA2 cohort when compared 
with diallylic lipid level and a 52% (P = .003) increase 
when compared with triglycerides level. Levels of diallylic 
lipid, unsaturated lipid, triglycerides, and terminal methyl 
on the acyl chain are reduced by 46% (P = .002), 57% (P 
= .003), 66% (P = .003), and 29% (P = .010), respectively, 
when compared with cholesterol level.
Conclusion: Localized COSY recorded significant changes in women 
with BRCA1 and BRCA2 gene mutations when compared 
with control subjects. If these changes are ultimately 
proven to be a premalignant stage, this method may prove 
useful in screening.
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B RCA1 and BRCA2 genes belong to the tumor suppressor fam-ily, and mutations cause an in-
creased risk for breast cancer (1). A 
woman carrying the BRCA1 or BRCA2 
mutation has approximately a 3% risk 
of developing breast cancer before the 
age of 30 years. This risk increases to 
almost 50% at 50 years of age, and in-
creases again to 50%–80% at 70 years 
of age (2). Women carrying BRCA 
gene mutations can develop cancer 
within months of negative findings at 
mammography, magnetic resonance 
(MR) imaging, or ultrasonography (US) 
screening, leading to the hypothesis 
that a preinvasive state or states may 
exist that cannot be identified with the 
current diagnostic modalities.
The foundation used to identify 
chemical changes associated with tu-
mor development and progression was 
derived by using MR spectroscopy to 
study cell models and biopsies (3,4). 
The MR spectroscopy method allows 
one to record those molecules that are 
mobile on the MR time scale (5) and 
thus in active pools often associated with 
disease. Cell models of tumor develop-
ment and progression were important 
in correlating MR spectral changes with 
Implication for Patient Care
 n If confirmed in larger popula-
tions, it is possible that the infor-
mation provided by localized cor-
related spectroscopy will allow 
women carrying BRCA gene mu-
tations an objective means with 
which to monitor the extent of 
biochemical changes taking place 
in their breast tissue.
Advances in Knowledge
 n Women carrying BRCA gene mu-
tations have metabolic deregula-
tions in their breast tissue that 
may be precursors to malignant 
transformation.
 n Women carrying BRCA1 gene mu-
tations exhibited a reduction of 
79% in metabolite level, while 
both lipid unsaturation and tri-
glyceride levels increased by 19%.
 n Women carrying BRCA2 gene 
mutations showed an increased 
lipid unsaturation of 21%.
 n The metabolic changes in women 
carrying BRCA1 gene mutations 
are different from those in 
women carrying BRCA2 gene 
mutations, with a 47% increase 
in cholesterol level recorded in 
those with BRCA2 gene 
mutations.
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specific biologic and genetic character-
istics (6–8). The earliest biomarkers of 
the premalignant state or states were 
MR-detectable lipids and cholesterol, 
where the chemical properties remain 
constant whether in a lipoprotein, cell, 
or organ. In parallel, the causes of the 
aberrant choline phospholipid metabo-
lism in patients with breast cancer were 
documented (9).
In a one-dimensional MR spectrum, 
the resonances overlap, often providing 
ambiguous assignments. Two-dimension-
al (2D) correlated spectroscopy (COSY), 
which is used to measure covalent link-
ages between protons in a molecule, sep-
arates the composite resonances in a sec-
ond frequency, allowing assignment and 
identification of the chemical change. To 
better understand the process of tumor 
development and how lipids and metab-
olite profiles changed, 2D COSY was 
compared with the chemical analyses 
of whole cells and purified membranes 
of models with established genetic and 
cell biologic characteristics (7). Lipid and 
cholesterol levels were shown to be the 
first markers of cellular instability and 
were considered the earliest of the pre-
malignant changes.
With improvements in MR magnet 
and coil technology, it became possible 
to record some of this information in 
vivo with a clinical imager. Thomas and 
colleagues used 2D localized COSY to 
support the concept that the lipid level 
was a diagnostic marker of malignancy 
(10). The 2D localized COSY has since 
enabled noninvasive diagnosis and 
chemical assessment of glioma (11), 
where the results were comparable 
with the information from cell models.
We hypothesized that women with 
BRCA gene mutations have altered 
chemistry reflective of a preinvasive 
state or states, and in vivo 2D localized 
COSY could offer a means to screen 
these women. The purpose of this 
study was to assess for an altered bio-
chemical state or states in the breast 
tissue of women with BRCA gene mu-
tations that potentially constitute pre-
invasive conditions.
Materials and Methods
Patients and Healthy Control Subjects
The study was approved by the Hunter 
New England Area Health Ethics Com-
mittee, and all patients and control sub-
jects provided written informed consent.
The recruitment of the BRCA co-
horts was through The Breast and 
Endocrine Centre in Gateshead, New 
South Wales, Australia, where genetic 
testing was performed as part of the 
routine clinical management. Nine 
women with a genetically confirmed 
BRCA1 mutation (age range, 41–62 
years; median age, 54 years) and 14 
women with a genetically confirmed 
BRCA2 mutation (age range, 25–70 
years; median age, 52.5 years) were re-
cruited. Nine women (five with BRCA1 
mutations, four with BRCA2 muta-
tions) were found to have had cysts or 
lesions. In these women, we examined 
the apparently healthy and unaffected 
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breast. All women were examined by 
a breast surgeon (D.C.) prior to MR 
imaging. A healthy control cohort was 
recruited from the wider community in 
the Hunter region, New South Wales, 
Australia. The control subjects had no 
family history of breast cancer (n = 10; 
age range, 34–68 years; median age, 
47.5 years).
MR Imaging and Spectroscopy
The study was performed with either 
a 3-T Skyra MR imager (Siemens, Er-
langen, Germany) and use of a 70-cm-
diameter body coil for signal excitation 
or a 3-T Prisma MR imager (Siemens) 
and use of a 60-cm-diameter body coil 
for excitation. A two-cavity 16-channel 
breast coil was used for signal reception 
(RAPID Biomedical, Rimpar Germany).
Breast MR Imaging
Routine breast T2- and T1-weighted 
MR imaging was performed. This con-
sisted of a localizer sequence (rep-
etition time msec/echo time msec, 
6/2.61; section thickness, 7 mm; field 
of view, 400 mm), an axial T1-weight-
ed three-dimensional fast low-angle 
shot non–fat-saturated radial sequence 
(5.43/2.46; flip angle, 20°; section 
thickness, 2 mm; field of view, 300 
mm; matrix, 448 3 448 mm), an axial 
T2-weighted turbo spin-echo sequence 
(4970/95; section thickness, 2 mm; 
field of view, 300 mm; matrix, 448 3 
448 mm), and an axial T1-weighted 
three-dimensional fast low-angle shot 
dynamic series (4.54/1.73; flip angle, 
10°; section thickness, 1.2 mm; field 
of view, 300 mm; matrix, 448 3 448 
mm) with one pre- and five postcon-
trast (Omniscan; GE Healthcare, Oslo, 
Norway) time points. Injection of this 
neutral chelate was performed in all 
patients but was not performed in the 
healthy control subjects. Four patients 
in the BRCA1 cohort had undergone 
2D COSY prior to and after contrast 
agent administration to ascertain if the 
contrast agent affected the spectral re-
sults. The MR images were examined 
independently by radiologists in three 
different practices with 10, 15, and 30 
years of experience in breast imaging 
(K.S.Y., G.S., and P.L., respectively.
Localized COSY 2D MR Spectroscopy
Anatomic MR imaging was used to po-
sition the 15 3 15 3 15 mm voxel in 
the lower left outer quadrant midway 
between fibroglandular and fat tissues. 
If the woman had undergone previous 
surgery in the left breast, the voxel was 
placed in the right breast in the outer 
quadrant (Fig 1). Voxel placement was 
the same for all participants, and voxels 
were placed by one of the radiologists. 
Localized shimming was performed 
with automatic adjustment of zero- and 
first-order shim gradients by using the 
automatic B0-field mapping technique 
automatic shimming algorithm (Sie-
mens) (12), followed by manual adjust-
ment of zero-order shim gradients to 
achieve width of water at half maximum 
of 40 Hz or more.
The localized COSY sequence was 
applied with an initial echo time of 30 
msec, repetition time of 1.5 seconds, 
eight signal averages per increment, 
a bandwidth of 2000 Hz, a T1 incre-
ment of 0.8 msec, and a vector size 
of 1024 points; the radiofrequency 
offset frequency was set on 3.2 ppm, 
and increments were 64. The water 
suppression enhanced through T1 
effects (or WET) technique (13) was 
applied. Processing was undertaken, 
as previously reported (11). The as-
signment of protons to the triglycer-
ide molecule is shown in Figure 2, 
and the assignment of protons to the cho-
lesterol molecule is shown in Figure 3. 
Cross and diagonal peak volumes were 
measured with Felix software (San Di-
ego, Calif) (14), with the (CH2)n diag-
onal peak at 1.30 ppm as the internal 
chemical shift reference. The measure-
ment of peak volumes was undertaken 
by prescribing a box on top of the area 
of interest, and the aforementioned 
software enabled us to measure the 
volume of signal under this box. The 
same box sizes were applied to all spec-
tra to reduce operator variability. Be-
cause of the absence of a reliable inter-
nal concentration standard, the ratios 
were calculated for all localized COSY 
spectra with respect to the following 
peaks: (5.30, 5.30) ppm, (2.75, 2.75) 
ppm, (1.30, 1.30) ppm, and (4.25, 
4.25) ppm. The unsaturation index was 
also measured and calculated by using 
cross peaks at (5.30, 2.75) ppm and 
(5.30, 2.05) ppm, as reported by Velan 
et al (15). Five authors are listed on a 
Figure 1
Figure 1: Unenhanced image shows region of interest placement in a 30-year-old control subject. This 
is the spectroscopic voxel location from which 2D localized COSY data were collected. The experimental 
conditions were as described previously.
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exhibited any indication of abnormal-
ity at MR imaging or US. All breast 
images were rated as Breast Imaging 
Reporting and Data System category 
1 or 2.
Effect of Contrast Agent Administration on 
2D COSY
Four women with BRCA1 gene muta-
tions were examined before and after 
contrast agent administration by using 
2D localized COSY, and no variation in 
cross peak volume greater than 8% was 
recorded for any of the data sets. This 
is considerably smaller than the chang-
es recorded between cohorts.
2D Localized COSY Assessment
The COSY spectra, recorded in women 
with either a BRCA1 gene mutation or 
a BRCA2 gene mutation, are compared 
with a spectrum from a healthy breast 
in Figure 4. The cross peaks are as-
signed, as per Figures 2 and 3.
pending patent regarding this technique 
(S.R., G.S., D.C., P.M., C.M.).
Statistical Analysis
Evaluation of statistical significance was 
undertaken by using Excel 2010 (Mi-
crosoft, Redmond, Wash) and the Real 
Statistics Resource Pack (16). Statistical 
significance was calculated for all as-
signed cross and diagonal peaks with a 
two-tailed nonparametric Mann-Whit-
ney test since data did not pass a normal 
distribution test. Biomarker resonance 
ratios with P  .05 were identified and 
listed. The statistical findings were not 
corrected for multiple comparisons 
since this was a small exploratory study.
Results
Clinical Assessment
None of the breast tissue examined 
with the 2D localized COSY method 
When we compared women with 
BRCA1 gene mutations with control 
subjects for peak volumes versus tri-
glycerides level (4.25, 4.25 ppm), no 
changes were recorded in the level of 
lipid unsaturation; however, the level 
of the composite resonance containing 
the metabolites choline, glycine, and 
myo-inositol decreased by 79% (P = 
.014). When compared with the cho-
lesterol level, women with BRCA1 gene 
mutations showed an increase in lipid 
unsaturation and triglyceride levels of 
19%, with P values of .027 and .086, 
respectively. When compared with the 
diallylic lipid level, the substrate metab-
olite resonance (choline, glycine, and 
myo-inositol) level was reduced by 98% 
(P = .018); the glycerol, glutamine or 
glutamate, and glucose composite was 
reduced by 70% (P = .072); and the 
cholesterol level was reduced by 47% 
(P = .027) (Table).
When we compared the BRCA2 
cohort with control subjects relative 
to triglyceride levels (4.25, 4.25 ppm), 
there were significant increases in the 
level of unsaturation of 21% and 21%, 
with P values of .030 and .040, respec-
tively. When we compared cholesterol 
levels in the BRCA2 cohort with the tri-
glycerides level and the terminal methyl 
level of the lipid acyl chains in control 
subjects, decreases of 55% (P = .069) 
and 50% (P = .053), respectively, were 
recorded.
Comparison of the BRCA1 and 
BRCA2 cohorts showed a 47% (P = 
.002) increase in cholesterol level in the 
BRCA2 cohort when compared with the 
diallylic lipid level and a 52% (P = .003) 
increase when compared with the tri-
glycerides level. When compared with 
the cholesterol level, the diallylic lipid, 
cross peak D, triglyceride, and cross 
peak A levels are reduced by 46% (P = 
.002), 57% (P = .003), 66% (P = .003), 
and 29% (P = .010), respectively, show-
ing that the unsaturated triglyceride 
level is reduced in relation to choles-
terol level in the BRCA2 cohort.
Discussion
Results from this study show bio-
chemical changes that may indicate a 
Figure 3
Figure 3: Diagram of the structure of a cholesterol molecule, with the methyl 
group used for spectroscopic detection in bold.
Figure 2
Figure 2: Diagram of a fatty acyl chain, with the associated spectroscopic cross peaks (A–G’) 
labeled.
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Figure 4
Figure 4: Typical localized COSY spectra in three women with the cross 
peaks assigned (A–G’) as per Figure 2. Images in (a) healthy 55-year-old con-
trol subject, (b) apparently healthy 56-year-old woman with BRCA1 mutation, 
and (c) apparently healthy 58-year-old woman with BRCA2 mutation.
deregulation of lipid pathways in the 
breast tissue of women carrying BRCA1 
and BRCA2 gene mutations. The chang-
es are recorded noninvasively after 
routine MR imaging. The 2D localized 
COSY method enabled us to iden-
tify differences between women with 
healthy breasts and those with BRCA1 
or BRCA2 gene mutations and between 
women with a BRCA1 gene mutation 
and those with a BRCA2 gene muta-
tion. It was necessary to use internal 
references to assess these changes, as 
the differences are calculated relative to 
spectral features that are also changing.
When we compared the BRCA1 co-
hort with control subjects, an increase 
in the glycerol backbone of triglycerides 
was accompanied by an increase in un-
saturation of the fatty acyl chains. The 
concentration of composite metabolite 
resonances was also reduced. For the 
BRCA2 cohort, changes were consis-
tent with an increase in the unsatu-
ration of the fatty acyl chains relative 
to triglycerides, but the composite 
metabolite resonances did not appear 
to have been affected. This suggests 
that there are multiple populations of 
lipids altering relative to one another 
both in women with BRCA1 mutations 
and in women with BRCA2 mutations. 
The increase in cholesterol level in the 
BRCA2 cohort indicates lipid pathways 
are affected differently in the two dif-
ferent gene mutations. In our earlier 
studies of the chemical analysis of pu-
rified plasma membranes of tumor cell 
models, the unsaturation was totally 
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Thus, by analogy, those women without 
cholesterol compare directly with PC/
AA and those with cholesterol present 
in their spectrum fit the PC/AA1 pro-
file (7). This suggests that tumors in 
women with the PC/AA1 profile may be 
one step closer to malignancy.
The mevalonate pathway facilitates 
synthesis of cholesterol (22). The first 
steps of cholesterol biosynthesis in-
volve condensation of acetyl-CoA with 
acetoacetyl-CoA to form 3-hydroxy-
3-methylglutaryl-CoA. The reduction 
of 3-hydroxy-3-methylglutaryl-CoA to 
mevalonate represents the rate-limiting 
reaction of the cholesterol synthesis 
pathway and is highly regulated. Inter-
estingly, this reductase is the target for 
a class of cholesterol-lowering drugs, 
the statins, which show antiprolifera-
tive activity in several cancer cell lines, 
including breast cancer cells (23).
These results suggest that MR-
observable cholesterol in the breast 
tissue of patients with a BRCA mu-
tation is a biomarker that potentially 
indicates a higher probability of de-
veloping a lesion that progresses to 
malignancy. The detection of choles-
terol with 2D localized COSY used to 
analyze the breast parenchyma of pa-
tients with BRCA mutations might en-
able identification of a group at higher 
risk. This requires a larger patient 
cohort to confirm these findings and 
the opportunity to monitor women 
who proceed through this adenoma to 
carcinoma sequence.
The reduction in the levels of the 
metabolites (glycerol, glycine, and/or 
inositol) in the breast tissue of women 
with a BRCA1 mutation is intriguing 
and requires further experimentation 
to determine which molecule or mol-
ecules are altered. It does, however, 
suggest metabolic activity is abnormal 
and that some of these molecules have 
been used up as a substrate. For ex-
ample, glycine is known to fuel cancer 
cells (24), while inositol hexaphos-
phate blocks proliferation of human 
breast cancer (25).
Importantly, these results indicate 
that BRCA1 and BRCA2 gene muta-
tions differ in the order in which lipid 
deregulation and substrate usage occur. 
It has been documented elsewhere that 
women with a BRCA2 mutation survive 
longer than women with a BRCA1 mu-
tation. These results suggest that there 
are biochemical differences that may 
explain this difference.
A larger study is now underway in 
two states in Australia to reach the re-
quired cohort size to verify the small-
est change recorded (ie, the decrease 
in the substrates in the BRCA2 cate-
gory). In addition, those women who 
have agreed to participate in this study 
are offered an MR examination with 
the 2D localized COSY protocol every 
6 months. The return rate is high, and 
we expect to be in a position to monitor 
the adenocarcinoma sequence in some 
of these participants.
A limitation to this study was the 
small number of women in each cate-
gory and the fact that we did not cor-
rect for multiple comparisons given 
the exploratory nature of the study. 
The analysis would also benefit from 
an informatics approach (26–28), 
since the current calculations are 
based on resonance ratios of lipids, 
which are altering. Another limitation 
was the small number of patients stud-
ied before and after contrast material 
administration. Serum lipid levels 
were not measured. Some patients 
were on lipid-lowering drugs; thus, 
the effect on the spectra needs to be 
examined in the ongoing study. Future 
studies will include the measurement 
of serum lipoprotein and cholesterol 
levels. The metabolic alterations that 
we describes are associated with can-
cer metabolism but were not proved 
in this study to indicate presence of 
active disease.
In summary, despite no evidence 
of any changes to breast tissue from 
current imaging modalities, in vivo 
2D localized COSY MR spectroscopy 
enables identification of biochemical 
abnormalities that may represent pre-
invasive changes in the breast tissue of 
women carrying the BRCA1 or BRCA2 
gene mutation. These differences are 
supported by results from a cell model 
of tumorigenesis. The changes include 
alterations to the amount and satura-
tion of triglycerides, cholesterol, and 
within the triglyceride population (8). 
The BRCA1 group showed an apparent 
increase in triglyceride and unsatura-
tion levels.
Changes to fatty acyl chain un-
saturation were consistent with those 
in the literature (17,18), where an in-
crease in the expression of fatty-acid 
synthase is seen in cancer pathogen-
esis (19). The first step of fatty acid 
biosynthesis requires activation of 
acetyl-CoA to malonyl-CoA catalyzed 
by acetyl-CoA carboxylase. The acetyl 
and malonyl groups are then coupled 
to the acyl carrier protein domain of 
the fatty acid synthase. Unsaturation is 
catalyzed by fatty acyl-CoA desaturas-
es to produce monounsaturated fatty 
acids. Fatty acyl-CoA desaturases cata-
lyze the synthesis of highly unsaturated 
fatty acids from essential polyunsatu-
rated fatty acids. Several studies have 
shown that tumor cells reactivate de 
novo lipid synthesis (19).
An important observation was the 
alteration of cholesterol levels in the 
BRCA2 cohort. This suggests that these 
women have cholesterol deregulation 
occurring in addition to fatty acyl chain 
unsaturation and increased triglyceride 
levels. When compared with cell model 
studies, each may constitute yet an-
other part of the premalignant process.
The appearance of cholesterol in 
breast tissue in the in vivo study is di-
rectly comparable with a colorectal cell 
model where two adenoma cell lines 
were compared with four malignant 
cell lines (7). The nontumorigenic PC/
AA adenoma cell line had a normal kar-
yotype at low passage number, and K-
ras mutations had been detected both 
in early and later passages (20). The 
2D COSY of this cell line showed the 
unsaturated triglyceride but no choles-
terol. The next cell line in the model 
PC/AACl had marker chromosome 1 
and other abnormalities, including loss 
of one chromosome 18. This is of in-
terest, since loss or mutation of the tu-
mor suppressor DCC gene, located on 
chromosome 18q, has been implicated 
in tumorigenesis (21). Also PC/AACl 
was nontumorigenic in nude mice. The 
2D COSY of PC/AACl showed both un-
saturated triglyceride and cholesterol. 
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metabolic substrates that precede 
the activation of choline metabolism 
through the choline kinase and phos-
pholipase C over expression. Impor-
tantly, BRCA1 differs from BRCA2.
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